The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | D-Kd for RRMM: MMY1001 final analysis
Sagar Lonial, MD, FACP, Winship Cancer Institute at Emory University, Atlanta, GA, discusses the final analysis of a phase 1b MMY1001 study of daratumumab in combination with carfilzomib and dexamethasone for relapsed/refractory multiple myeloma, one arm of the study’s evaluation of daratumumab (D-Kd) in combination with various backbone therapies (NCT01998971). Prof. Lonial highlights how this study lead into the CANDOR trial (NCT03158688), which was part of a late-breaking abstract at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
